MX2020005470A - Composiciones y metodos para enfermedades neurologicas. - Google Patents

Composiciones y metodos para enfermedades neurologicas.

Info

Publication number
MX2020005470A
MX2020005470A MX2020005470A MX2020005470A MX2020005470A MX 2020005470 A MX2020005470 A MX 2020005470A MX 2020005470 A MX2020005470 A MX 2020005470A MX 2020005470 A MX2020005470 A MX 2020005470A MX 2020005470 A MX2020005470 A MX 2020005470A
Authority
MX
Mexico
Prior art keywords
compositions
methods
neurological diseases
engineered receptors
modulating
Prior art date
Application number
MX2020005470A
Other languages
English (en)
Spanish (es)
Inventor
Kenneth P Greenberg
Anthony Lau
Jr Orion Keifer
Stefanie Makinson
Original Assignee
Coda Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coda Biotherapeutics Inc filed Critical Coda Biotherapeutics Inc
Publication of MX2020005470A publication Critical patent/MX2020005470A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2020005470A 2017-11-27 2018-11-27 Composiciones y metodos para enfermedades neurologicas. MX2020005470A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762590911P 2017-11-27 2017-11-27
US201862659911P 2018-04-19 2018-04-19
PCT/US2018/062575 WO2019104307A1 (en) 2017-11-27 2018-11-27 Compositions and methods for neurological diseases

Publications (1)

Publication Number Publication Date
MX2020005470A true MX2020005470A (es) 2020-11-09

Family

ID=66632192

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020005470A MX2020005470A (es) 2017-11-27 2018-11-27 Composiciones y metodos para enfermedades neurologicas.
MX2024014448A MX2024014448A (es) 2017-11-27 2020-07-13 Composiciones y metodos para enfermedades neurologicas

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024014448A MX2024014448A (es) 2017-11-27 2020-07-13 Composiciones y metodos para enfermedades neurologicas

Country Status (12)

Country Link
US (2) US10538571B2 (cg-RX-API-DMAC7.html)
EP (1) EP3716990A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021503960A (cg-RX-API-DMAC7.html)
KR (2) KR20200112811A (cg-RX-API-DMAC7.html)
CN (1) CN111741760A (cg-RX-API-DMAC7.html)
AU (2) AU2018373279B2 (cg-RX-API-DMAC7.html)
CA (1) CA3082907A1 (cg-RX-API-DMAC7.html)
IL (2) IL274702B2 (cg-RX-API-DMAC7.html)
MX (2) MX2020005470A (cg-RX-API-DMAC7.html)
SG (1) SG11202004488TA (cg-RX-API-DMAC7.html)
WO (1) WO2019104307A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202408862B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020222881C1 (en) 2019-02-13 2026-01-22 Ptc Therapeutics, Inc. Thioeno(3,2-b) pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
JP7781052B2 (ja) * 2019-08-21 2025-12-05 トレイムス バイオ, インコーポレイテッド 神経学的疾患のための組成物および方法
US20230102192A1 (en) * 2020-02-20 2023-03-30 The Regents Of The University Of California Therapies for the treatment of diseases and disorders associated with abnormal expression of a neural-associated gene
AU2021329529A1 (en) * 2020-08-21 2023-04-27 Trames Bio, Inc. Compositions and methods for neurological diseases
WO2022067044A1 (en) * 2020-09-25 2022-03-31 The Regents Of The University Of California Compositions and methods for ameliorating medical conditions
JP2024505197A (ja) * 2021-01-25 2024-02-05 トレイムス バイオ, インコーポレイテッド 焦点てんかんおよび神経因性疼痛を処置するためのアデノ随伴ウイルスカプシドおよび操作されたリガンド依存性イオンチャネル
US11969400B2 (en) * 2021-03-23 2024-04-30 Kumara V. Nibhanipudi Ibuprofen for symptomatic treatment of diarrheas in HIV patients
WO2023278295A1 (en) 2021-06-29 2023-01-05 The Broad Institute, Inc. Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
CN113730809B (zh) * 2021-10-09 2024-08-16 科悦医疗(苏州)有限公司 一种非侵入式迷走神经联合骶神经刺激装置
US20250145687A1 (en) * 2022-01-31 2025-05-08 Howard Hughes Medical Institute Modified ligand-gated ion channels and methods of use
CN119343455A (zh) * 2022-01-31 2025-01-21 特拉梅斯生物股份有限公司 用于治疗癫痫和神经性疼痛的表达盒
IL315059A (en) * 2022-02-18 2024-10-01 Trames Bio Inc Ion channels that open using ligands and methods of using them
AU2023222147A1 (en) * 2022-02-18 2024-09-12 Trames Bio, Inc. Compositions and methods for neurological diseases
WO2025015092A1 (en) * 2023-07-10 2025-01-16 Kriya Therapeutics, Inc. Novel cam-kinase promoter and uses thereof for treating nervous system disorders
CN121866054A (zh) * 2023-08-16 2026-04-14 拜尔吉生物股份有限公司 用于治疗癫痫发作的方法
GB202401492D0 (en) 2024-02-05 2024-03-20 Ucl Business Ltd Chloride channels and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3628691B2 (ja) * 1993-03-08 2005-03-16 メルク エンド カンパニー インコーポレーテッド ヒト神経細胞性ニコチン性アセチルコリン受容体組成物およびそれらの使用方法
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
WO1997035478A1 (en) 1996-03-26 1997-10-02 The Regents Of The University Of California Selective target cell activation by expression of a g protein-coupled receptor activated superiorly by synthetic ligand
FR2756297B1 (fr) 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
WO1999006562A1 (en) 1997-07-31 1999-02-11 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
CA2995542A1 (en) 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
WO2000073431A2 (en) 1999-05-27 2000-12-07 Pharmacia & Upjohn Company Methods and compositions for measuring ion channel conductance
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
WO2001023001A2 (en) 1999-09-29 2001-04-05 The Trustees Of The University Of Pennsylvania Rapid peg-modification
AU2001257378A1 (en) 2000-04-29 2001-11-12 Millennium Pharmaceuticals, Inc. 23949 and 32391, human ion channels and uses thereof
US7883846B2 (en) 2002-05-31 2011-02-08 Sloan-Kettering Institute For Cancer Research Heterologous stimulus-gated ion channels and methods of using same
PL2657248T3 (pl) 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
WO2008143875A1 (en) 2007-05-14 2008-11-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
WO2010042799A2 (en) 2008-10-09 2010-04-15 Howard Hughes Medical Institute Novel chimeric ligand-gated ion channels and methods of use thereof
US9624288B2 (en) * 2012-12-10 2017-04-18 University of Pittsburgh—of the Commonwealth System of Higher Education Engineered receptors and their use
GB201404470D0 (en) 2014-03-13 2014-04-30 Ucl Business Plc Therapeutic methods and materials
US10682424B2 (en) 2015-03-31 2020-06-16 New York University Compositions and method for reducing seizures
AU2016324317A1 (en) 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders
IL311984A (en) 2016-07-07 2024-06-01 Hughes Howard Med Inst Modified ligand-gated ion channels and methods of use
US11713470B2 (en) 2017-03-20 2023-08-01 University of Pittsburgh—of the Commonwealth System of Higher Education Targeted gene therapies for pain and other neuro-related disorders

Also Published As

Publication number Publication date
US20190161529A1 (en) 2019-05-30
IL274702B2 (en) 2026-04-01
WO2019104307A1 (en) 2019-05-31
AU2018373279A1 (en) 2020-06-04
CN111741760A (zh) 2020-10-02
SG11202004488TA (en) 2020-06-29
EP3716990A1 (en) 2020-10-07
KR20200112811A (ko) 2020-10-05
JP2024160218A (ja) 2024-11-13
ZA202408862B (en) 2026-01-28
IL274702B1 (en) 2025-12-01
AU2018373279B2 (en) 2024-07-25
JP2021503960A (ja) 2021-02-15
EP3716990A4 (en) 2021-12-08
CA3082907A1 (en) 2019-05-31
IL324810A (en) 2026-01-01
IL274702A (en) 2020-06-30
AU2024227560A1 (en) 2024-11-14
US20210061873A1 (en) 2021-03-04
MX2024014448A (es) 2024-12-06
KR20260030128A (ko) 2026-03-05
US10538571B2 (en) 2020-01-21
AU2024227560B2 (en) 2026-06-04

Similar Documents

Publication Publication Date Title
ZA202408862B (en) Compositions and methods for neurological diseases
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
WO2017177179A9 (en) Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
PH12021551455A1 (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease
EP4219724A3 (en) Compositions and methods for treating non-age-associated hearing impairment in a human subject
EA201891152A1 (ru) Экстрацеллюлярные везикулы нервных клеток
WO2015148974A3 (en) Engineered light-activated anion channel proteins and methods of use thereof
JOP20200035A1 (ar) تركيبات حمض أميني لعلاج الإصابات العصبية
MY193524A (en) Diaryl macrocycles as modulators of protein kinases
SMT202400187T1 (it) Pirazolo(1,5-a)pirimidine sostituite e loro utilizzo nel trattamento di disturbi medici
MX2019010949A (es) Moduladores de somatostatina y usos de los mismos.
WO2016037157A3 (en) Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
WO2016070051A3 (en) Combination therapy for treatment of disease
MX2018005286A (es) Constructo genetico.
WO2016025635A3 (en) Combination therapy for treating cancer
PH12017500494A1 (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
WO2016097315A3 (en) Blood brain barrier transport molecules and uses thereof
MX2019012176A (es) Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
WO2016055622A9 (en) Improved biomaterials for neuronal implants and use of said biomaterials in the diagnosis and therapy of neuronal diseases
MX2023002161A (es) Composiciones y metodos para enfermedades neurologicas.
WO2015185945A3 (en) Polypeptides and uses thereof
PH12017500998A1 (en) Treatment of ocular conditions using progenitor cells
EP4218776A3 (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor